VentureBeat

Featured companies: Acceleron Pharma, AdvanDx, Altheus Therapeutics, BiPar Sciences, Coventina Healthcare Enterprises, ForteBio, Ganymed Pharmaceuticals, Mako Surgical, Nile Therapeutics, Novate Medical

[NOTE: This briefing was posted on Friday, 9/21/07; I've edited its timestamp to preserve chronological order among the briefings.]

Nile Therapeutics raises $20M, goes public in reverse merger — Berkeley, Calif.-based Nile Therapeutics, a developer of cardiovascular drugs, raised $20 million from new and existing investors and carried out a reverse merger that takes the company public. Investors in the financing included Wexford Capital, RIT Capital Partners, Life Science Capital Master Fund, and other institutional investors. It’s not clear if Nile had raised venture capital prior to this funding.

Nile is at work on a second generation “natriuretic peptide,” which is basically a protein fragment that mimics the function of natural diuretics found in the heart. Nile licensed that drug from the Mayo Clinic; it’s now in early-stage human testing. Nile intends to acquire additional experimental drugs to expand its portfolio.

AdvanDx pulls in $15M for pathogen diagnostics — AdvanDx, a Woburn, Mass., biotech that develops molecular diagnostic tests for identifying infectious pathogens in hospitals, raised $15 million in a third funding round. Investors included bioMérieux, LD Pensions and SLS Venture.

The company’s diagnostic tests can supposedly identify the microbes responsible for bloodstream infections in hours rather than days, as current culturing tests require. The time saved can make it possible to effectively treat patients much sooner. In that sense, AdvanDx’s technology is similar to that of OpGen, which we wrote about in the first item here.

Novate Medical draws in €4M for anti-clot device — Ireland’s Novate Medical, a device maker at work on filters that can be installed in veins to prevent blood clots from reaching the lungs and causing pulmonary embolisms, raised €4 million ($5.5 million). Investors included ACT Venture Capital, Seroba BioVentures and Enterprise Ireland.

The company doesn’t appear to have a Web site.

Antibody company Ganymed adds €3.5M to round — Germany’s Ganymed Pharmaceuticals, a developer of monoclonal-antibody drugs for cancer, added €3.5 million ($4.9 million) to its third funding round, bringing that total to €37.2 million ($52.1 million). The additional funding was provided by ATS Beteiligungsverwaltung of Munich.

Altheus Therapeutics gets $3.6 million against bowel disease — Oklahoma City’s Altheus Therapeutics, a biotech working on new treatments for inflammatory bowel disease, raised $3.6 million to fund clinical trials. St. Louis-based Prolog Ventures, the Oklahoma Seed Capital Fund and Oklahoma Equity Partners provided the funding.

Altheus is developing a treatment that combines two existing drugs, which the company hasn’t identified.

Coventina Healthcare Enterprises gets $150K, moves to Pennsylvania — The seemingly ubiquitous Pittsburgh Life Sciences Greenhouse has struck again, investing $150,000 in Coventina Healthcare Enterprises, which then relocated to southwestern Pennsylvania from Texas. Coventina recently acquired the assets of Texas-based Selicor, and now develops therapeutic heating systems that rely on radio-frequency energy.

Mako Surgical seeks an $86M IPO for knee-surgery robots — The Ft. Lauderdale, Fla., company filed to raise up to $86 million in an initial offering. Mako’s robotic-surgery device and knee implants are designed to perform minimally invasive knee operations.

Brownian motion: Personnel moves in the life sciences —

• Acceleron Pharma, of Cambridge, Mass., named John Knopf as CEO. The company develops biotech drugs for muscle and bone injuries.
• BiPar Sciences, of Brisbane, Calif., named former Genentech CEO G. Kirk Raab as its acting chief executive. Raab is also the company’s chairman. The company develops cancer drugs.
• ForteBio, of Menlo Park, Calif., named Joseph Keegan as its new CEO. The company builds instruments designed to speed the discovery of new therapeutics.

Nile Therapeutics, a Berkeley, Calif., biotech hired Peter Strumph, formerly chief of operations for struggling heart-drug maker CV Therapeutics, as CEO. Nile is currently developing a second-generation natriuretic peptide, CD-NP, for the treatment of heart failure. Here’s hoping it fares better than the first-generation version of this drug, J&J’s Natrecor. The company’s release is here.

Macroflux, a Mountain View, Calif., spinoff from Alza, hired M. Cory Zwerling as CEO. The company is developing “needle-free” delivery of complex drugs, similar in certain ways to StrataGent Life Sciences, which we wrote about here. Here is the company’s release.

ForHealth Technologies, a Daytona Beach, Fla., company, named Steve Thomas as its new CEO, VentureWire reports (subscription required). The company makes an automated filler for intravenous drug syringes. It’s apparently not clear that Thomas will move from his San Diego home, at least according to this article.

This last one is a bit old, but still worth noting. Scott Gottlieb, the former FDA official turned American Enterprise Institute pundit, whose various opinings on the biotech industry we have noted here and here, is apparently also a paid consultant to Novartis — an association that for some reason never seems to get noted when he writes long attacks on the New England Journal of Medicine for the WSJ’s editorial page. Perhaps readers can benefit from this information the next time Gottlieb unburdens himself of his accumulated wisdom. (Hat tip: Pharmalot.)